Table 3.
Preclinical research of mRNA–LNP vaccines for cancer treatment.
| Disease | Vaccine | Lipid Nanoparticle Components | Molar Lipid Ratios |
Target Antigen |
Route | Ref. |
|---|---|---|---|---|---|---|
| Lymphoma | Rituximab mRNA-LNP |
ALC-0315 lipids, phosphatidylcholine, cholesterol, PEG–lipids |
50:10:38.5:1.5 | Rituximab | ID | [87] |
| Melanoma | TRP2/gp100- mRNA-LNP |
C12-200 + CKK-12, DOPE + DSPC, cholesterol, C14-PEG1000 + C14-PEG350, arachidonic acid |
31.5:10:36:2.5:20 | Tumor-associated antigens GP100 and TRP2 | IH | [12] |
| Melanoma | IL-12-mRNA-LNP | DALs, DOPE, cholesterol, DMG-PEG | 20:30:40:0.75 | Interleukin-12 | IH | [85] |
| Melanoma | A2-mOVA-LNP | A2, DOPE, cholesterol, C14-PEG | 45:10:42.5:2.5 | OVA | ID | [86] |
ID: intradermal injection; IH: hypodermic injection; OVA: ovalbumin.